

Table 1 Endothelial dysfunction in coronary circulation and clinical outcome

D

Author	Patients	Study type and		Predictive value
		duration	Outcome studied	
Suwaidi <i>et al</i> ^{w1}	157 patients with mild CAD	Retrospective (28 months)	Cardiac death, MI, CHF, CABG, PCI	+
Schachinger <i>et al</i> ^{w2}	147 patients with CAD	Retrospective (7.7 years)	MI, UA, ischaemic stroke, CABG, PTCA, peripheral bypass	+
Hollenberg <i>et al</i> ^{w3}	73 orthotopic heart transplant recipients	Prospective (32 months)	Cardiac death, cardiac allograft vasculopathy	+
Halcox <i>et al</i> ^{w4}	308 patients referred for cardiac catheterisation	Retrospective (46 months)	CVD death, MI, ischaemic stroke, UA	+
Targonski <i>et al</i> ^{w5}	503 patients without angiographic CAD	Retrospective (90 months)	Cerebrovascular events	+
Schindler <i>et al</i> ^{w6}	130 patients with normal coronary angiograms	Prospective (45 months)	CVD death, UA, MI, PTCA, CABG, stroke, peripheral bypass	+

CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cardiovascular disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; UA, unstable angina; +, independent predictor.

Table 2 Endothelial dysfunction in peripheral circulation and clinical outcome

D

Author	Patients	Study type and duration	Outcome studied	Predictive value
Neunteufl <i>et al</i> ^{w7}	73 patients with CAD	Retrospective (5 years)	Death, MI, PTCA, CABG	+
Heitzer <i>et al</i> ¹⁸	281 patients with CAD	Prospective (4.5 years)	CVD, stroke, MI, CABG, PTCA, peripheral bypass	+
Perticone <i>et al</i> ¹⁷	225 patients with hypertension	Prospective (32 months)	CVD death, MI, stroke, TIA, UA, CABG, PTCA, PVD	+
Gokce <i>et al</i> ^{w8}	187 patients undergoing vascular surgery	Prospective (30 months)	CVD death, MI, UA, stroke	+
Modena <i>et</i>	400 hypertensive	Prospective	CVD event	+

Author	Patients	Study type		Predictive value
		and duration	Outcome studied	
<i>al</i> ^{w9}	postmenopausal women	(67 months)		
Gokce <i>et al</i> ^{w10}	199 patients undergoing vascular surgery	Prospective (1.2 years)	CVD death, MI, UA, stroke	+
Brevetti <i>et al</i> ^{w11}	131 patients with PVD	Prospective 23 months	CVD death, MI, coronary revascularisation, UA, stroke, TIA	+
Chan <i>et al</i> ^{w12}	152 coronary patients	Prospective 34 months	CVD death, MI, coronary revascularisation, UA, stroke, TIA, carotid endarterectomy	+
Fathi <i>et al</i> ^{w13}	444 patients at risk of coronary events	Prospective 24 months	Cardiovascular death, MI, stroke, revascularisation	-

PVD, peripheral vascular disease; TIA, transient ischemic attack; -, not an independent predictor of events.

Table 3 Relation of interleukin 6, myeloperoxidase, and CD40 with cardiovascular risk

D

Inflammatory	
biomarker	Predictive value
Interleukin 6	Early marker for outcome in acute ischemic stroke ^{w14} Adverse in hospital prognosis in patients with acute coronary syndrome ^{w15} Increased mortality in unstable CAD ^{w16, w17}
Myeloperoxidase	Increased risk for cardiovascular events ^{w18, w19}
CD40	Risk of recurrent cardiovascular events ^{w20, w21} Independent increased risk of major cardiovascular events ^{w18, w22}

Table 4 Cohort studies examining the relation between C reactive protein and CVD

D

Author	No of patients (age range (years))	Follow up (years)	End point measured	Predictive value
Agewall <i>et al</i> ^{w23}	131 (56–77)	3	Fatal and non-fatal MI, SCD	+
Koenig <i>et al</i> ^{w24}	936 (45–64)	8.2	Fatal or non-fatal acute MI	+
Jager <i>et al</i> ^{w25}	631 (50–70)	5	CVD death, ICD	+
Ridker <i>et al</i> ^{w26}	5742 (45–73)	5	Non-fatal MI, UA, SCD	+

Author	No of patients (age range (years))	Follow up (years)	End point measured	Predictive value
Rost <i>et al</i> ^{w27}	1462 (59–91)	12–14	First ischemic stroke, TIA	+
Harris <i>et al</i> ^{w17}	675 (>65)	4.6	CVD death, ICD	–
Mendall <i>et al</i> ^{w28}	1239 (45–59)	13.7	First fatal or non-fatal IHD	–
Lowe <i>et al</i> ^{w29}	1595 (49–67)	6.25	First fatal or non-fatal IHD	–
Piro <i>et al</i> ^{w30}	2037 (35–64)	5.2	Angina, CI, non-fatal MI, coronary death	–
Strandberg ^{w31}	455 (75–85)	10	CVD death	–
Kistorp <i>et al</i> ^{w32}	764 (50–89)	5	CVD death and first major cardiovascular event	–

CI, coronary insufficiency; ICD, implantable cardioverter defibrillator; IHD, ischaemic heart disease; SCD, sudden cardiac death.

Table 5 Nested case control studies examining the relation between C reactive protein and CVD

D

Author	Study population/age (years)	Follow-up (years)	End point	Predictive value
---------------	-------------------------------------	--------------------------	------------------	-------------------------

Author	Study population/age	Follow-up	End point	Predictive
	(years)	(years)		value
Albert <i>et al</i> ^{w33}	289 (97 men cases) 40–84	17	SCD	+
Danesh <i>et al</i> ^{w34}	1531 (506 men cases) 40–59	9.5	Fatal CHD, non-fatal MI	+
Folsom <i>et al</i> ^{w35}	1205 (615 cases) 45–64	3.6–4.3	MI, CHD, death , revascularisation	+
Gram <i>et al</i> ^{w36}	391 (133 cases) >40	7–15	MI, CHD	–
Gusseklou <i>et al</i> ^{w37}	163 (80 cases) >85	<5	Stroke death	+
Kervinen <i>et al</i> ^{w38}	300 (150 cases) 40–55	<17	MI or coronary death	+
Kuller <i>et al</i> ^{w39}	444 (148 cases) 35–57	<17	CHD death	+
Roivainen <i>et al</i> ^{w40}	430 (215 cases) 48	<8.5	MI or coronary death	+

Author	Study population/age	Follow-up	End point	Predictive value
	(years)	(years)		
Packard <i>et al</i> ^{w41}	1740 (580 cases) 56.8 (5.2)	<6	Fatal CHD, non-fatal MI	+
Ridker <i>et al</i> ³⁵	789 (246 men cases) 40– 84	<14	MI	+
	697 (154 men cases) 40– 84		Ischaemic stroke	
Ridker <i>et al</i> ^{w42,} w43	366 (122 women cases) 59.3 (8.4)	<3	MI, stroke, PTCA, CABG, CVD death	+
Sakkinen <i>et al</i> ^{w44}	1717 (369 men cases) 45–68	20	MI	+
Tice <i>et al</i> ^{w45}	394 (52 women cases) >65	6	CVD death	+
Tracy <i>et al</i> ^{w46}	292 (146 cases) >65 382 (237 cases) 65–79	<3	MI, AP, CHD death	–

AP, angina pectoris; CHD, coronary heart disease.